BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 11377540)

  • 21. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.
    Sánchez V; Delgado JF; Blasco T; Dalmau R; Morales JM; Escribano P; Tello R; Hernández J; Velázquez T; Sotelo T; Gómez-Sánchez MA; Sáenz de la Calzada C
    Transplant Proc; 1999 Sep; 31(6):2515-6. PubMed ID: 10500695
    [No Abstract]   [Full Text] [Related]  

  • 22. Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients.
    Abouna GM; al Arrayed AS; Farid E; Awad CK; Sharqawi SA; Tantawi M
    Transplant Proc; 1998 Dec; 30(8):4077-8. PubMed ID: 9865302
    [No Abstract]   [Full Text] [Related]  

  • 23. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Morgera S; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Jun; 30(4):1190-1. PubMed ID: 9636481
    [No Abstract]   [Full Text] [Related]  

  • 24. Mycophenolate mofetil.
    Becker BN
    Transplant Proc; 1999 Nov; 31(7):2777-8. PubMed ID: 10578287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
    Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
    Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
    [No Abstract]   [Full Text] [Related]  

  • 26. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

  • 27. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study.
    Seebacher G; Weigel G; Griesmacher A; Mallinger R; Zuckermann A; Grimm M; Laufer G
    Transplant Proc; 1999 Dec; 31(8):3291-3. PubMed ID: 10616480
    [No Abstract]   [Full Text] [Related]  

  • 28. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up.
    Gavlik A; Demirbas A; Tsaroucha A; Webb MG; Nery JR; Khan MF; Karatzas T; Khan RT; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997 Nov; 29(7):2971-2. PubMed ID: 9365633
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept.
    Ringe B; Braun F; Lorf T; Canelo R; Schütz E; Sattler B; Ramadori G
    Transplant Proc; 1998 Jun; 30(4):1415-6. PubMed ID: 9636573
    [No Abstract]   [Full Text] [Related]  

  • 31. Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients.
    Golconda MS; Valente JF; Bejarano P; Gilinsky N; First MR
    Transplant Proc; 1999; 31(1-2):272-3. PubMed ID: 10083104
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenolate mofetil rescue therapy in liver transplant recipients.
    Gavlik A; Goldberg MG; Tsaroucha A; Webb MG; Khan RT; Weppler D; Nery JR; Khan MF; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997; 29(1-2):549-52. PubMed ID: 9123124
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
    Yu L; Wang Y; Fu SJ; Cheng XJ
    Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
    [No Abstract]   [Full Text] [Related]  

  • 37. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 38. Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mofetil and cyclosporine.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):744-5. PubMed ID: 10083317
    [No Abstract]   [Full Text] [Related]  

  • 39. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.
    Lietz K; John R; Schuster M; Ankersmit J; Burke E; Suciu-Foca N; Edwards N; Mancini D; Itescu S
    Transplant Proc; 2002 Aug; 34(5):1828-9. PubMed ID: 12176593
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
    Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
    Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.